3-(2-乙氧基羰基乙基)-2,4-二甲基-5-甲酰基吡咯 | 21603-70-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 3-(2-乙氧基羰基乙基)-2,4-二甲基-5-甲酰基吡咯
• 中文别名: 5-醛基-2,4-二甲基-1氢-吡咯-3-丙酸乙酯
• 英文名称: ethyl 3-(5-formyl-2,4-dimethyl-1H-pyrrol-3-yl)propanoate
• 英文别名: 5-Formyl-3-<2-ethoxycarbonyl-ethyl>-2,4-dimethyl-pyrrol；3,5-dimethyl-4-(2-ethoxycarbonylethyl)-2-formyl-1H-pyrrole；3-(5-formyl-2,4-dimethyl-pyrrol-3-yl)-propionic acid ethyl ester
• CAS: 21603-70-3
• 化学式: C₁₂H₁₇NO₃
• mdl: MFCD03426225
• 分子量: 223.272
• InChiKey: NECQDWYVPWLBTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-(2-乙氧基羰基乙基)-2,4-二甲基-5-甲酰基吡咯 在 氢氧化钾 、 硫酸 作用下， 以 甲醇 为溶剂， 反应 73.5h， 生成 8-(2-carbomethoxyethyl)-7,9-dimethyl-2,3-dimethoxy-10H-dipyrrin-2-one
  参考文献：
  名称：

  两亲性双吡啶

  摘要：

  两种长久以来被用作其光化学和代谢研究模型化合物的胆红素类似物取代了黄胆红素酸和and基吡咯烷酮的典型内酰胺β-烷基取代基，导致两亲性增加。由3,4-二甲氧基吡咯啉-2-酮与适当的吡咯α-醛进行碱催化缩合反应合成的黄原胆红酸和k基吡咯烷酮的2,3-二甲氧基类似物是黄色的二吡啶酮类，它们在分子内形成分子间氢键合的二聚体。通过1 H NMR和蒸气压渗压法测定，通过X射线晶体学测定和在CHCl 3中测定固体。这两种新的双吡啶酮在水中的溶解度比其母体双吡啶酮高约十倍。

  DOI：

  10.1007/s00706-007-0652-z
• 作为产物：
  描述：

  3-(2,4-二甲基-5-醛基-1H-吡咯)-3-丙酸 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 3-(2-乙氧基羰基乙基)-2,4-二甲基-5-甲酰基吡咯
  参考文献：
  名称：

  Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia

  摘要：

  A series of 6-acylureido derivatives containing a 3-(pyrrol-2-ylmethylidene)indolin-2-one scaffold were synthesized as potential dual Aurora B/FLT3 inhibitors by replacing the 6-arylureido moiety in 6-arylureidoindolin-2-one-based multi-kinase inhibitors. (Z)-N-(2-(pyrrolidin-l-yl)ethyl)-5-((6-(3-(2-fluoro-4-methoxybenzoyflureido)-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (54) was identified as a dual Aurora B/FLT3 inhibitor (IC50 = 0.4 nM and 0.5 nM, respectively). Compound 54 also exhibited potent cytotoxicity with single-digit nanomolar IC50 values against the FLT3 mutant-associated human acute myeloid leukemia (AML) cell lines MV4-11 (FLT3-ITD) and MOLM-13 (FLT3-ITD). Compound 54 also specifically induced extrinsic apoptosis by inhibiting the phosphorylation of the Aurora B and FLT3 pathways in MOLM-13 cells. Compound 54 had a moderate pharmacokinetic profile. The mesylate salt of 54 efficiently inhibited tumor growth and reduced the mortality of BALB/c nude mice (subcutaneous xenograft model) that had been implanted with AML MOLM-13 cells. Compound 54 is more potent than sunitinib not only against FLT3-WT AML cells but also active against sunitinib-resistant FLT3-ITD AML cells. This study demonstrates the significance of dual Aurora B/FLT3 inhibitors for the development of potential agents to treat AML. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.07.108

文献信息

• Water-soluble xanthobilirubinic acids?
  作者：Sanjeev K. Dey、David A. Lightner

  DOI：10.1007/s00706-008-0057-7

  日期：2009.2

  acid, a model dipyrrinone for one-half of the bilirubin molecule in photochemical and metabolism studies, is more polar than bilirubin and insoluble in water and in chloroform. Replacing the β-alkyl substituents on the lactam ring of xanthobilirubinic acid with methyl-capped ethylene glycol, diethylene glycol, and triethylene glycol (PEG) groups steadily increased the water solubility of the pigment

  摘要在光化学和新陈代谢研究中，黄胆红素酸是一种模型的吡啶酮，在胆红素分子中占一半，比胆红素极性更强，不溶于水和氯仿。用甲基封端的乙二醇，二甘醇和三甘醇（PEG）基团取代黄胆红酸内酰胺环上的β-烷基取代基稳定地增加了颜料的水溶性，因此最后一种颜料完全溶于水和氯仿中。通过碱催化缩合相应的甲基封端的3,4-diPEG-吡咯啉-2-酮与3,5-二甲基-4（2-乙氧基羰基乙基）-2-甲酰基-1 H合成-吡咯，这些新的黄胆红素酸的聚乙二醇化类似物是黄色的二吡啶酮，它们在氯仿溶液中形成分子间氢键合的二聚体，但在甲醇和水中是单体，如1 H NMR光谱和蒸气压渗透压法所揭示的。黄嘌呤胆红素甲酯已被用作胆红素类化合物的合成前体。它的两亲性聚乙二醇化类似物暗示了一条通往水溶性胆红素和双肝素类化合物的途径。 图形概要
• Bi-functional complexes and methods for making and using such complexes
  申请人：Gouliaev Alex Haahr

  公开号：US11225655B2

  公开（公告）日：2022-01-18

  The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.

  本发明涉及一种合成双功能复合物的方法，该复合物包括分子部分和识别分子部分的识别寡核苷酸部分。根据本发明的合成方法的一部分优选在一种或多种有机溶剂中进行，此时包含可选保护标签或寡核苷酸标识符的新生双功能复合物与固体支持物相连接，合成方法的另一部分优选在适合于将寡核苷酸标签酶加到溶液中的新生双功能复合物的条件下进行。
• BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES
  申请人：Nuevolution A/S

  公开号：EP2558577B1

  公开（公告）日：2018-12-12
• BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES
  申请人：Gouliaev Alex Haahr

  公开号：US20130281324A1

  公开（公告）日：2013-10-24

  The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.
• Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia
  作者：Ajit Dhananjay Jagtap、Pei-Teh Chang、Jia-Rong Liu、Hsiao-Chun Wang、Nagendra B. Kondekar、Li-Jiuan Shen、Hsiang-Wen Tseng、Grace Shiahuy Chen、Ji-Wang Chern

  DOI：10.1016/j.ejmech.2014.07.108

  日期：2014.10

  A series of 6-acylureido derivatives containing a 3-(pyrrol-2-ylmethylidene)indolin-2-one scaffold were synthesized as potential dual Aurora B/FLT3 inhibitors by replacing the 6-arylureido moiety in 6-arylureidoindolin-2-one-based multi-kinase inhibitors. (Z)-N-(2-(pyrrolidin-l-yl)ethyl)-5-((6-(3-(2-fluoro-4-methoxybenzoyflureido)-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (54) was identified as a dual Aurora B/FLT3 inhibitor (IC50 = 0.4 nM and 0.5 nM, respectively). Compound 54 also exhibited potent cytotoxicity with single-digit nanomolar IC50 values against the FLT3 mutant-associated human acute myeloid leukemia (AML) cell lines MV4-11 (FLT3-ITD) and MOLM-13 (FLT3-ITD). Compound 54 also specifically induced extrinsic apoptosis by inhibiting the phosphorylation of the Aurora B and FLT3 pathways in MOLM-13 cells. Compound 54 had a moderate pharmacokinetic profile. The mesylate salt of 54 efficiently inhibited tumor growth and reduced the mortality of BALB/c nude mice (subcutaneous xenograft model) that had been implanted with AML MOLM-13 cells. Compound 54 is more potent than sunitinib not only against FLT3-WT AML cells but also active against sunitinib-resistant FLT3-ITD AML cells. This study demonstrates the significance of dual Aurora B/FLT3 inhibitors for the development of potential agents to treat AML. (C) 2014 Elsevier Masson SAS. All rights reserved.